title: Effect of ferric sorbitol citrate (FSC) administration on NF-kappaB in macrophages and spleen cells of rats.
abstract: Interaction of iron metabolism and the immune system is complex and pathological changes in one system affect the other. Ferric sorbitol citrate (FSC), non-toxic compound of ferric ions with sorbitol and citrate. has immunomodulatory effect in treated mice. We investigated an effect of FSC on NF-kappaB expression/activation in peritoneal macrophages and spleen cells of rats. TNF-alpha concentrations in sera of control and FSC intraperitoneal (i.p.) treated Wistar rats were measured by ELISA. Furthermore, peritoneal macrophages (PM) were counted and splenocytes were isolated. PM and splenocytes were lysed and their cytoplasmic and nuclear fractions were separated by centrifugation. The influence of FSC on NF-kappaB expression and/or activity as well as expression of its inhibitor IkappaB-alpha was measured by Western blot. 1.5 and three hours after FSC treatment TNF-alpha level in sera was significantly (p < or = 0.05) increased. Activation of transcription factor NF-kappaB in PM was detected three hours after treatment, followed by significant increment in PM number. In splenocytes NF-kappaB was activated six and 48 hours after FSC application. The results indicate that, after i.p. application, FSC acts as a modulator of the immune system activating NF-kappaB in PM. PM consequently secrete TNF-alpha that activates NF-kappaB in splenocytes.
authors.affiliation: PLIVA Inc., Pharmaceutical Company, Zagreb, Croatia.
authors.forename: Berislav
authors.initials: B
authors.lastname: Bosnjak
authors.forename: Masa
authors.initials: M
authors.lastname: Katić
authors.forename: Boska
authors.initials: B
authors.lastname: Hrvacić
authors.forename: Zeljko
authors.initials: Z
authors.lastname: Zupanović
authors.forename: Marija
authors.initials: M
authors.lastname: Poljak-Blazi
mesh_terms: D000818:Animals; D015153:Blotting, Western; D002452:Cell Count; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D002951:Citrates / Q000494:pharmacology*; D003593:Cytoplasm / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005290:Ferric Compounds / Q000494:pharmacology*; D020672:I-kappa B Proteins / Q000378:metabolism; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000378:metabolism; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism*; D052002:NF-kappa B p50 Subunit; D010537:Peritoneum / Q000166:cytology / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013154:Spleen / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D051996:Transcription Factor RelA; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000378:metabolism
chemical_list: D002951:Citrates; D005290:Ferric Compounds; D020672:I-kappa B Proteins; D016328:NF-kappa B; D052002:NF-kappa B p50 Subunit; C000606205:Nfkbia protein, mouse; C000606206:Nfkbia protein, rat; D051996:Transcription Factor RelA; D014409:Tumor Necrosis Factor-alpha; C421458:ferric-sorbitol-citrate; D000072000:NF-KappaB Inhibitor alpha